Bioanalytical trials: the analytical spine of drug development.
Bioanalytical trials are the analytical spine of every PK, BE, biomarker, and immunogenicity study. It is the operational domain iFeed has the deepest substrate in — production-floor embodied DNA across CRO trenches. The complete package: platforms, regulatory regimes, matrix types, method lifecycle.
What a bioanalytical method is, end-to-end.
Chromatogram · Calibration · BMVA bioanalytical method is three artefacts in tandem. The chromatogram is the raw analytical signal — analyte resolved from internal standard and matrix. The calibration curve is the response-vs-concentration model that turns peak area into concentration, bounded by LLOQ and ULOQ. The BMV pillar set is the discipline of validating that the method holds — the nine criteria ICH M10 names. Read together, they are how a bioanalytical lab gets and keeps regulator confidence.
Selected acceptance values shown in the diagram (e.g., R² ≥ 0.99, Rs ≥ 1.5) reflect widely-adopted industry practice; ICH M10 itself does not specify an R² acceptance threshold and anchors acceptance on accuracy criteria (±15%, ±20% at LLOQ). Resolution Rs ≥ 1.5 is a chromatographic norm (e.g., USP <621>), not codified in ICH M10.
The iFeed.bioanalytical reference, in headlines.
2026-05-02 · live5 anchored.
ICH M10 · FDA 2018 (parallel) · EMA → ICH M10 (replaced 2011 Rev 1, eff. 21 Jan 2023) · WHO TRS 996 · ANVISA RDC 742/2022. Cross-regulator comparison live in Parameters.
9 BMV.
Selectivity · calibration · A&P · carry-over · matrix effect (★) · stability · dilution · ISR · reanalysis.
7+ years.
Operational DNA from CRO trenches. NIPER M.S. Pharm + bench depth. Mumbai BE startup · Pune CRO · Indian pharma manufacturing lineage.
4 patterns.
ISR sample selection ~28% · reagent-lot bridging ~22% · partial-validation gaps ~17% · method-transfer docs ~14%. iFeed analysis of public 483s and Warning Letters; FDA does not publish category-level breakdowns.
This domain connects to three.
Bioanalytical doesn't sit aloneBioanalytical is the analytical spine that BE and clinical trials both run on. Governance gates everything. Click a node to open that space.
Nine chapters · open any.
Each chapter is its own page · secondary nav aboveParameters: 9 BMV pillars · 5 regulators.
Quick-reference grid of all nine parameters · then the cross-regulator color-coded comparison drilldown for each. ICH M10 · FDA · EMA · WHO · ANVISA. The flagship chapter for the analytical spine.
Open chapter →
Analytical substrate.
The operational architecture beneath every method. Five analytical platforms (LC-MS/MS, HRMS, HPLC-UV, LBA, hybrid) · regulatory regimes · the four-phase method lifecycle · matrix types (plasma, serum, urine, whole blood, tissue).
Open chapter →
History & evolution.
From the 1989 Bolar/Mylan generic-drug scandal to harmonised global text in 2022. Crystal City I-VI. Shah 1992 (the de facto standard for 8 years). FDA 2001 · EMA 2011 · FDA 2018 · ICH M10 2022. Six eras decoded.
Open chapter →
Current state: 2026.
ICH M10 v1 (Step 4 24 May 2022) adopted by all ICH Regulatory Members (currently 11 + EU) via their own implementation processes. FDA 2018 + M10 parallel. EMA M10 effective 21 Jan 2023 (superseded EMEA/CHMP/EWP/192217/2009 Rev.1 Corr.2). PMDA via PSEHB/PED Notification 4 December 2024. ANVISA RDC 742/2022. WHO TRS 996 cumulative. Top 2025 483 categories ranked.
Open chapter →
Future scope: 2026-2035.
ICH M10 v2 by Q3 2028. Tier 1/2/3 biomarker validation formalised. VCN sub-section. Anti-vector immunogenicity under ADA framework. HRMS routinised by 2028. Reagent-lot bridging displaces ISR as #1 483.
Open chapter →
AI in bioanalytical.
Peak detection in production since 2018 (SCIEX, Waters, Shimadzu). Calibration-fit selection. ISR intelligent randomisation piloted by major CROs. PCCP framework extends to BMV ~2027. Generative authoring out of scope through 2030.
Open chapter →
Flow of bioanalytical trials.
Method development → pre-study validation → method transfer → sample receipt → study sample analysis → ISR → in-study reanalysis → PK derivation → bioanalytical report → submission. Sequential and gated.
Open chapter →
People: use cases, players, stakeholders.
Eight regulatory triggers that demand validated bioanalysis. Five player categories: CRO specialists, pharma sponsors, regulators, tech vendors, standards bodies. Ten stakeholder roles with their interest + leverage.
Open chapter →
Notes: bioanalytical writing.
The chronological feed of writing relevant to bioanalytical practice. Method validation under ICH M10, FDA 483 patterns, AI-augmented chromatography. Filtered from the global notes archive.
Open chapter →
Worked examples from the archive.
Three pieces · rest · in the writingThe calibration curve: what it tells you and what it hides.
Reading the calibration curve as the analytical method's autobiography. ±15% nominal except ±20% at LLOQ. What inspectors look for; what reports omit.
Bioanalytical trial flow.
The end-to-end flow of a bioanalytical study: from protocol to sample analysis to regulatory submission. The architecture that produces concentration data the regulator inspects.
BA/BE trial flow · thirteen stages.
End-to-end flow of a bioavailability/bioequivalence study. Where bioanalysis sits inside the broader BE pipeline.